Merck and BMS will be under pressure in the future!

All commercially successful drugs will gradually decline one day.

In this analysis, the value to be compared is the proportion of the total sales of prescription drug products that have lasted more than 10 years in the total sales of pharmaceutical companies

AstraZeneca, which has performed poorly on this indicator in previous years, has made further progress in 2020

Specifically, AbbVie, Pfizer and Roche have become the top ten pharmaceutical companies that rely on old products the most, and they have the greatest pressure to find new sources of sales

Merck and BMS will increase pressure in the future

Pharmaceutical companies can quickly reduce their reliance on obsolete products through corresponding measures, and this means that these numbers are not static when looking at the potential of the freshness index

According to Evaluate Pharma's sales forecast, Merck and BMS, which currently dominate the PD-1 drug market, will need new revenue channels by 2026 as their PD-1 drugs begin to "aging"

Of course, sales freshness is only one of the many indicators used to evaluate these major pharmaceutical companies

However, executives and investors in the pharmaceutical industry want to see a company’s freshness index showing a downward trend, or it is better not to become too high, in order to maintain the stability of the company’s operations